2001 DEC 25 - (NewsRx.com & NewsRx.net) -- Targeted Diagnostics and Therapeutics, Inc., (TDT) has granted Millennium Pharmaceuticals, Inc., license to TDT's intellectual property surrounding guanylyl cyclase C (GC-C), a protein uniquely expressed on the cell surface of colorectal tumors, and its related ST ligand for use in colorectal cancer therapeutics.
Millennium intends to utilize these advanced components to develop both toxin- and antibody-based therapeutics directed against colorectal cancer. Due to the utility demonstrated in preclinical work, Millennium believes there is potential to create highly specific therapies that may offer significantly improved …
No comments:
Post a Comment